Applications

1721 – Small gene panel testing for non-small cell lung carcinoma

Find out about the service or technology in this application and the medical condition it addresses. You can also view the application documents, the deadlines for providing consultation input and the outcome of the application when the MSAC process is complete.

  • Status Complete
  • Type New application
  • Pre-PASC consultation Not applicable
  • Pre-MSAC consultation Closed
  • Outcome Supported

Application details

Reason for application

New MBS item.

Service or technology in this application

Next generation sequencing panel testing involves nucleic acid extraction from a tissue biopsy sample, which then undergoes target enrichment treatment. Genomic variants are then curated by scientists/pathologists and a clinical report generated.

Type: Investigative technology

Medical condition this application addresses

Non-small cell lung cancer (NSCLC) is any type of epithelial lung cancer other than small cell lung cancer. The most common types of NSCLC are squamous cell carcinoma, large cell carcinoma, and adenocarcinoma.

Most NSCLC patients have symptoms at the time of diagnosis. Depending on the stage of disease and the type of lung cancer, treatment options may include surgery, radiotherapy, chemotherapy, immunotherapy, or molecularly targeted therapy.

Application documents

Consultation survey and deadlines

  • PASC consultation: Expedited – bypassing PASC
  • MSAC Consultation: Closed Friday 7 October 2022

Meetings to consider this application

  • PASC meeting: Expedited – bypassing PASC
  • ESC meeting: 6–7 October 2022
  • MSAC meeting: 24–25 November 2022